- Home
- SJT vs NYXH Comparison
SJT vs NYXH Comparison
Compare SJT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | NYXH |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | Belgium |
| Employees | 495 | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 161.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SJT | NYXH |
|---|---|---|
| Price | $2.67 | $1.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 201.9K | 129.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.37 | $1.26 |
| 52 Week High | $6.61 | $6.95 |
Technical Indicators
Market Signals| Indicator | SJT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 54.01 |
| Support Level | $2.57 | $1.26 |
| Resistance Level | $2.79 | $1.70 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 83.33 | 100.00 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.